{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:25:46Z","timestamp":1780590346423,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jad.2018.12.023","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T12:00:22Z","timestamp":1545048022000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder"],"prefix":"10.1016","volume":"246","author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Nierenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khodayar","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck","family":"Yonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2018.12.023_bib0001","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0002","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0003","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2018.12.023_bib0004","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0005","series-title":"Presented at the 20th Annual Conference of the International Society for Bipolar Disorders","article-title":"RE-KINECT: A prospective real-world dyskinesia screening study and registry in patients with mood\/anxiety disorders prescribede antipsychotic agents","author":"Caroff","year":"2018"},{"key":"10.1016\/j.jad.2018.12.023_bib0006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","article-title":"Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia","volume":"72","author":"Caroff","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ncl.2010.10.002","article-title":"Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial","volume":"29","author":"Caroff","year":"2011","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jad.2018.12.023_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jad.2018.12.023_bib0009","first-page":"17","article-title":"Relationship between awareness of tardive dyskinesia and awareness of illness in schizophrenia","volume":"4","author":"Daniel","year":"2016","journal-title":"Int. J. Sci. Study"},{"key":"10.1016\/j.jad.2018.12.023_bib0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study","volume":"78","author":"Factor","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0011","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2018.12.023_bib0012","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites","volume":"36","author":"Grigoriadis","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2018.12.023_bib0013","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2018.12.023_bib0014","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 5","key":"10.1016\/j.jad.2018.12.023_bib0015","first-page":"43","article-title":"Tardive dyskinesia in affective disorders","volume":"60","author":"Kane","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0016","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17cs11959","article-title":"Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia workshop","volume":"79","author":"Kane","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.jad.2018.12.023_bib0017","first-page":"S33","article-title":"Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia","volume":"61","author":"Keck","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0018","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","article-title":"Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale","volume":"173","author":"Lane","year":"1985","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jad.2018.12.023_bib0019","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0020","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: s randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jad.2018.12.023_bib0021","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0022","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0023","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2147\/DDDT.S32328","article-title":"New and emerging treatments for symptomatic tardive dyskinesia","volume":"7","author":"Rana","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jad.2018.12.023_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jad.2018.12.023_bib0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40264-017-0623-1","article-title":"Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials","volume":"41","author":"Thai-Cuarto","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2018.12.023_bib0026","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-016-0568-1","article-title":"Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2018.12.023_bib0027","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"10.1016\/j.jad.2018.12.023_bib0028","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.12.023_bib0029","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718312862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718312862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:23:26Z","timestamp":1759022606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718312862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":29,"alternative-id":["S0165032718312862"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2018.12.023","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2018.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}